First Fracture Prevention Study In Men Receiving ADT For Prostate Cancer Presented At AACR Annual Meeting
Apr 18th 2008Drug InformationCancer
GTx, Inc. (NASDAQ: GTXI) announced that results of the Phase III ADT clinical trial evaluating toremifene citrate 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) in men who have advanced prostate cancer were presented during a late breaking oral session at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
